Grifols, S.A

Grifols, S.A. is a global healthcare company dedicated to improving the health and well-being of people around the world. Founded in 1940, Grifols has established itself as a leader in the pharmaceutical and biotechnology sectors, focusing on the development of innovative therapies derived from human plasma.

The company operates through three main divisions: Bioscience, Diagnostic, and Hospital. In the Bioscience division, Grifols produces a wide range of plasma-derived medicines that treat various chronic and acute conditions, including immune deficiencies and bleeding disorders.

In the Diagnostic division, Grifols offers advanced diagnostic solutions that enhance patient care and streamline laboratory processes. Their products are essential for blood typing, infectious disease testing, and other critical diagnostics.

The Hospital division focuses on providing essential hospital supplies and services, including intravenous solutions and nutritional products, ensuring that healthcare providers have the necessary tools to deliver optimal patient care.

Grifols is committed to research and development, investing significantly in innovation to create new therapies and improve existing ones. The company collaborates with leading research institutions and universities to advance scientific knowledge and develop cutting-edge treatments.

With a presence in over 30 countries and a workforce of more than 24,000 employees, Grifols is dedicated to maintaining high ethical standards and sustainability practices. The company’s vision is to be a trusted partner in healthcare, delivering high-quality products and services that meet the needs of patients and healthcare professionals alike.

Grifols also prioritizes corporate social responsibility, engaging in initiatives that support communities and promote health education globally. Through its commitment to excellence and innovation, Grifols continues to make significant contributions to the healthcare industry.